StockWatch
·

VENUS REMEDIES LTD.

BSE: 526953

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
219.16
+20.8%+12.8%
Expenditure
182.39
+22.6%+8.1%
Net Profit
28.96
+13.4%+50.5%
OPM %
20.86%
+0.41pp+5.37pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.0073.82147.64221.47295.29Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

Venus Remedies Q2 FY27: PAT +27% YoY to ₹25.65 Cr, margins expand, revenue beats Street

pharmaceuticals · margin expansion · international registrations

ResultsQ2 FY2726 Oct 20263 minPharma & Healthcare

Specialty Pharma Momentum — Growth and Margin Expansion on Track

specialty pharma · margin expansion · international growth

Result previewQ2 FY2720 Oct 20263 minPharma & Healthcare

Venus Remedies Q1 FY27: consolidated PAT jumps ~139% YoY to ₹22.97 Cr, margins expand

Pharma & Biotech · earnings · quarterly results

ResultsQ1 FY2720 Jul 20263 minPharma & Healthcare
Latest
Quarterly Result26 Oct, 6:41 pm

Venus Remedies Q2 FY27: PAT +27% YoY to ₹25.65 Cr, margins expand, revenue beats Street

Venus Remedies' consolidated PAT (primary basis) rose 27.4% YoY to ₹25.65 Cr on revenue of ₹218.76 Cr, up 13.5% YoY — profit growing roughly twice as fast as the topline, the clearest sign of margin expansion this quarter. Against our pre-result preview, which flagged ₹150–180 Cr revenue and ₹25–32 Cr PAT as the on-plan range alongside a Street consensus of BUY (9 analysts: 5 buy, 3 strong buy, 1 hold; ₹2,350 target vs the ₹1,592 pre-result close), revenue came in well above the top end of that band while PAT landed mid-range — a clean beat on scale and an in-line print on profitability. On margins, operating margin (PBT + depreciation − other income, over operating revenue) widened to 19.43% from 16.06% a year ago, and net margin to 11.70% from 10.35%, as operating leverage on the larger revenue base outpaced higher employee costs (₹26.53 Cr vs ₹22.97 Cr YoY) and R&D spend (₹5.98 Cr vs ₹4.35 Cr). Sequentially, though, NPM eased from 12.66% in Q1 FY27 even as OPM barely moved (19.12% to 19.43%) — a mild QoQ softening on the bottom line that the YoY comparison, which is the primary read here, screens past. Management issued no formal FY27 guidance in this filing or on record, so the print can only be graded against the Street's own expectation band, which it cleared on revenue. The October 16 disclosure of five new marketing authorisations across four countries lines up with the international-registration driver our preview flagged, though the statement itself carries no country-level revenue split to size that contribution this quarter. Auditors carried an emphasis-of-matter (opinion unmodified) on ₹28.60 Cr of share-application money still pending allotment at wholly-owned German subsidiary Venus Pharma GmbH, which management ties to an ongoing European restructuring; that unit posted a ₹5.84 Cr net loss on ₹3.64 Cr revenue for the half year, which is why consolidated PAT (₹25.65 Cr, EPS ₹19.19) runs about 11% below standalone PAT (₹28.96 Cr, EPS ₹21.66) — worth flagging since readers will encounter the higher standalone number elsewhere. With no guidance on record, the next checkpoints are whether NPM recovers from its sequential dip, whether the new international authorisations convert into booked revenue, and whether the German subsidiary's losses narrow as the referenced restructuring progresses.

26 Oct 2026, 06:41 pm

Corporate Events

Board MeetingVENUSREM
2026
26Oct

Board Meeting

To consider and approve unaudited Standalone and Consolidate…

BSE Filing ↗
Board MeetingVENUSREM
2026
20Aug

Board Meeting

The 37th Annual General Meeting of the Company is scheduled …

BSE Filing ↗
DividendVENUSREM
2026
7Aug

₹10 / share

BSE Filing ↗
Board MeetingVENUSREM
2026
20Jul

Board Meeting

The meeting of the Board of Directors is scheduled to be hel…

BSE Filing ↗
Board MeetingVENUSREM
2026
24Jun

Board Meeting

The 17th Annual General Meeting (AGM) of the members of Home…

BSE Filing ↗
Board MeetingVENUSREM
2026
26May

Board Meeting

The board meeting is scheduled to consider and approve audit…

BSE Filing ↗
Board MeetingVENUSREM
2025
10Nov

Board Meeting

Consider and approve Unaudited Standalone and Consolidated F…

BSE Filing ↗
Board MeetingVENUSREM
2025
4Feb

Board Meeting

Considering and approving Unaudited Standalone and Consolida…

BSE Filing ↗
Board MeetingVENUSREM
2024
29Oct

Board Meeting

Considering and approving the Unaudited Standalone and Conso…

BSE Filing ↗
Board MeetingVENUSREM
2024
20Jul

Board Meeting

Consideration of appointment of independent director, finali…

BSE Filing ↗
Board MeetingVENUSREM
2024
30May

Board Meeting

To consider and approve Audited Standalone and Consolidated …

BSE Filing ↗
Board MeetingVENUSREM
2023
9Nov

Board Meeting

Consider and approve Unaudited Standalone and Consolidated F…

BSE Filing ↗